

Singapore-based Qritive joins forces with Roche to redefine global cancer diagnostics with AI

13 September 2024 | News

Qritive's AI-powered solutions to be fully integrated with Roche navify Digital Pathology platform



Qritive, a digital pathology and artificial intelligence (AI) company headquartered in Singapore, has announced its collaboration with Roche, one of the largest diagnostics and life sciences companies in the world. This collaboration represents a significant milestone to advance cancer diagnostics and treatment and accelerate adoption of AI by pathologists.

With Qritive's AI-powered solutions fully integrated with Roche navify Digital Pathology platform, pathologists can leverage AI technology to diagnose cancer more accurately and efficiently, leading to reduced time to treatment and enhanced patient outcomes. These clinically validated AI modules, designed for colon, prostate, breast, and gastric cancers, analyze whole slide images to identify and grade tumor with precision. These tools have been shown to improve pathology reporting time by up to 10-fold and reduce the risk of misdiagnosis dramatically.

Qritive's collaboration with Roche reinforces its commitment to empowering pathologists globally with state-of-the-art AI-powered solutions and alleviating the pressure on the healthcare system. By bringing its innovative AI-based pathology solutions to a broader audience, Qritive continues to play a pivotal role in the future of cancer diagnostics.

The startup leverages deep learning technology to support the interpretation of pathology tests for time and resource-strapped pathologists, enabling faster diagnosis and reducing time to treatment for patients.